Business Context and Reporting Period
Cullinan Oncology, Inc. filed this Current Report on Form 8-K dated October 15, 2021, with the relevant leadership changes effective October 18, 2021. The filing reports executive departure, CEO succession, director appointment, related compensation arrangements, and Regulation FD disclosure. It is not a periodic financial report.
Key Financial and Corporate Terms
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics are reported.
- Outgoing CEO Owen Hughes is entitled to 12 months of base salary, $216,507 representing a prorated target bonus, accelerated vesting of all outstanding and unvested equity awards, potential proceeds from the Company’s Cash Phantom Pool, and up to 12 months of certain COBRA premium payments.
- Incoming CEO Nadim Ahmed will receive an annual salary of $600,000, a $625,000 sign-on bonus subject to repayment provisions, a temporary housing allowance of $6,000 per month, and a stock option to purchase 2,710,000 shares at fair market value on the grant date.
- The option grant will vest monthly over 48 months, subject to continued service. Performance-based restricted stock units are also expected to be granted within 90 days, with the number of shares and performance metrics to be determined by the Board.
Material Changes Versus the Prior Period
- Owen Hughes departed as President and Chief Executive Officer and ceased serving as a director effective October 18, 2021. He will continue as a senior advisor for up to 12 months.
- Nadim Ahmed became President, Chief Executive Officer, Principal Executive Officer, and a Class III director effective October 18, 2021. His initial director term is scheduled for election at the 2023 annual meeting.
- The filing does not provide a comparable prior-period financial statement or quantify the aggregate accounting expense associated with the leadership transition.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- No financial guidance or operational outlook is provided.
- Mr. Ahmed is eligible for an annual incentive bonus initially set at 50% of base salary beginning in 2022 and may be considered for annual equity awards beginning in 2023.
- If Mr. Ahmed is terminated without cause or resigns for good reason, he may receive 12 months of salary, a prorated bonus, and certain COBRA benefits. Following a qualifying change in control, these benefits generally increase to 24 months of salary and related health-insurance payments, with accelerated vesting of specified equity awards.
- The sign-on bonus is repayable in whole or in part if Mr. Ahmed resigns without good reason or is terminated for cause during the first 18 months of employment.
- The agreements include confidentiality, nonsolicitation, noncompetition, cooperation, non-disparagement, release, and indemnification provisions.
- The filing includes an October 18, 2021 press release announcing Mr. Ahmed’s appointment. The press release was furnished under Regulation FD and is not deemed filed for Exchange Act Section 18 liability purposes.
Investor Verification Items
- Review Exhibit 10.1 for the complete terms of Mr. Ahmed’s employment agreement, including severance, change-in-control protections, bonus repayment, and equity awards.
- Verify the fair-market-value exercise price and final grant date of the 2,710,000-share option.
- Monitor subsequent filings for the number and terms of the performance-based restricted stock units and any annual equity awards.
- Assess the financial statement impact of Mr. Hughes’s severance, accelerated equity vesting, phantom pool participation, and Mr. Ahmed’s compensation arrangements.
- Confirm the final corporate name and any subsequent changes to executive leadership or board composition in later SEC filings.